Oncolytic virus-initiated protective immunity against prostate cancer
/in International Publications, Newcastle Disease Virus, Prostate Cancer /von 2011-01-18 / Mol. Ther. 2011 Apr;19(4):797-804Enhanced stimulation of anti-ovarian cancer CD8(+) T cells by dendritic cells loaded with nanoparticle encapsulated tumor antigen
/in Dendritic Cells, International Publications /von 2011-01-18 / Am. J. Reprod. Immunol. 2011 Jun;65(6):597-609KNK437, a benzylidene lactam compound, sensitises prostate cancer cells to the apoptotic effect of hyperthermia
/in Hyperthermia, International Publications, Prostate Cancer /von 2011-01-04 / Int J Hyperthermia 2011;27(1):63-73Induction of cellular immune responses in patients with stage-I multiple myeloma after vaccination with autologous idiotype-pulsed dendritic cells
/in Dendritic Cells, International Publications, Multiple Myeloma /von 2011-01-01 / J. Immunother. 2011 Jan;34(1):100-6Sipuleucel-T: in metastatic castration-resistant prostate cancer
/in Dendritic Cells, International Publications, Prostate Cancer /von 2011-01-01 / Drugs 2011 Jan;71(1):101-8Inhibition of B16 murine melanoma metastasis and enhancement of immunity by fever-range whole body hyperthermia
/in Hyperthermia, International Publications /von 2011-01-01 / Int J Hyperthermia 2011;27(3):275-85New perspectives in glioma immunotherapy
/in Dendritic Cells, Glioblastoma, International Publications /von 2011-01-01 / Curr. Pharm. Des. 2011;17(23):2439-67[Study on the specific immunity induced by dendritic cell vaccine loading allogenic microvascular endothelial cell bEnd.3 antigen against U14 cervical cancer cell in mice]
/in Cervical Cancer, Dendritic Cells, International Publications /von 2011-01-01 / Zhonghua Fu Chan Ke Za Zhi 2011 Jan;46(1):52-7Immunotherapy as a strategy for the treatment of non-small-cell lung cancer
/in International Publications, NSCLC /von 2011-01-01 / Therapy 2011 Jan;8(1):43-54
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Das IOZK
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- Recent developments in targeting breast cancer stem cells (BCSCs): a descriptive review of therapeutic strategies and emerging therapies
- Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum
- Individualized Multimodal Immunotherapy (IMI): Scientific Rationale and Clinical Experience from a Single Institution